cross reactions

Summary

Summary: Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.

Top Publications

  1. pmc Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    Xueling Wu
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 329:856-61. 2010
  2. pmc Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection
    Jens Wrammert
    Emory Vaccine Center, School of Medicine, Emory University, Atlanta, GA 30322, USA
    J Exp Med 208:181-93. 2011
  3. pmc Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus
    Rui Xu
    Department of Molecular Biology, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 328:357-60. 2010
  4. pmc Cross-reacting antibodies enhance dengue virus infection in humans
    Wanwisa Dejnirattisai
    Department of Medicine, Imperial College London, London W12 0NN, UK
    Science 328:745-8. 2010
  5. pmc The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity
    Martina Beltramello
    Institute for Research in Biomedicine, Bellinzona 6500, Switzerland
    Cell Host Microbe 8:271-83. 2010
  6. pmc Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection
    D Noah Sather
    Seattle Biomedical Research Institute, Seattle, Washington 98109, USA
    J Virol 83:757-69. 2009
  7. pmc Characteristics of the earliest cross-neutralizing antibody response to HIV-1
    Iliyana Mikell
    Seattle BioMed, Seattle, Washington, USA
    PLoS Pathog 7:e1001251. 2011
  8. pmc The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection
    Elin S Gray
    National Institute for Communicable Diseases, Johannesburg, Private Bag X4, Sandringham 2131, Johannesburg, South Africa
    J Virol 85:4828-40. 2011
  9. ncbi How TCRs bind MHCs, peptides, and coreceptors
    Markus G Rudolph
    Department of Molecular Structural Biology, University of Gottingen, 37077 Gottingen, Germany
    Annu Rev Immunol 24:419-66. 2006
  10. pmc Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning
    Thomas Tiller
    Max Planck Institute for Infection Biology, D 10117 Berlin, Germany
    J Immunol Methods 329:112-24. 2008

Detail Information

Publications352 found, 100 shown here

  1. pmc Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    Xueling Wu
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 329:856-61. 2010
    ..Exceptionally broad HIV-1 neutralization can be achieved with individual antibodies targeted to the functionally conserved CD4bs of glycoprotein 120, an important insight for future HIV-1 vaccine design...
  2. pmc Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection
    Jens Wrammert
    Emory Vaccine Center, School of Medicine, Emory University, Atlanta, GA 30322, USA
    J Exp Med 208:181-93. 2011
    ..Antibodies generated potently protected and rescued mice from lethal challenge with pandemic H1N1 or antigenically distinct influenza strains, making them excellent therapeutic candidates...
  3. pmc Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus
    Rui Xu
    Department of Molecular Biology, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 328:357-60. 2010
    ..Thus, antigenic similarity between the 2009 and 1918-like viruses provides an explanation for the age-related immunity to the current influenza pandemic...
  4. pmc Cross-reacting antibodies enhance dengue virus infection in humans
    Wanwisa Dejnirattisai
    Department of Medicine, Imperial College London, London W12 0NN, UK
    Science 328:745-8. 2010
    ....
  5. pmc The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity
    Martina Beltramello
    Institute for Research in Biomedicine, Bellinzona 6500, Switzerland
    Cell Host Microbe 8:271-83. 2010
    ..Our findings reveal an unexpected degree of cross-reactivity in human antibodies against DENV and illustrate the potential for an antibody-based therapy to control severe dengue...
  6. pmc Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection
    D Noah Sather
    Seattle Biomedical Research Institute, Seattle, Washington 98109, USA
    J Virol 83:757-69. 2009
    ..Overall, our study indicates that more than one pathway leads to the development of broad cross-reactive neutralizing antibodies during HIV infection and that the virus continuously escapes their action...
  7. pmc Characteristics of the earliest cross-neutralizing antibody response to HIV-1
    Iliyana Mikell
    Seattle BioMed, Seattle, Washington, USA
    PLoS Pathog 7:e1001251. 2011
    ....
  8. pmc The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection
    Elin S Gray
    National Institute for Communicable Diseases, Johannesburg, Private Bag X4, Sandringham 2131, Johannesburg, South Africa
    J Virol 85:4828-40. 2011
    ....
  9. ncbi How TCRs bind MHCs, peptides, and coreceptors
    Markus G Rudolph
    Department of Molecular Structural Biology, University of Gottingen, 37077 Gottingen, Germany
    Annu Rev Immunol 24:419-66. 2006
    ..Notwithstanding, the impressive array of self, foreign (microbial), and autoimmune TCR complexes have uncovered the diverse ways in which antigens can be specifically recognized by TCRs...
  10. pmc Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning
    Thomas Tiller
    Max Planck Institute for Infection Biology, D 10117 Berlin, Germany
    J Immunol Methods 329:112-24. 2008
    ....
  11. pmc Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms
    Matthew R Vogt
    Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8051, St Louis, MO 63110, USA
    J Virol 85:11567-80. 2011
    ....
  12. pmc A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America
    PLoS Pathog 6:e1001028. 2010
    ..In approximately half of the donors, key N-linked glycans were critical for expression of the epitopes recognized by the bNAb specificities in the sera...
  13. pmc Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1
    Stephen Mark Tompkins
    Food and Drug Administration, Bethesda, Maryland, USA
    Emerg Infect Dis 13:426-35. 2007
    ..This M2 prime-boost vaccination conferred broad protection against challenge with lethal influenza A, including an H5N1 strain. Vaccination with M2, with key sequences represented, may provide broad protection against influenza A...
  14. pmc Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies
    Nicole A Doria-Rose
    LIR, NIAID, National Institutes of Health, Bldg 10, Rm 7N246, 10 Center Dr, Bethesda, MD 20892, USA
    J Virol 83:188-99. 2009
    ..These data describe the breadth and titer of serum NAb and the frequency and phenotype of HIV-specific B cells in a cohort of patients with broad cross-neutralizing antibody responses that are potential goals for vaccines for HIV...
  15. ncbi Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus
    Kathy Hancock
    Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    N Engl J Med 361:1945-52. 2009
    ....
  16. pmc Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification
    Scott J Balsitis
    Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California, United States of America
    PLoS Pathog 6:e1000790. 2010
    ..These observations provide insight into the pathogenesis of antibody-enhanced dengue disease and identify a novel strategy for the design of therapeutic antibodies against dengue...
  17. ncbi Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo
    Thomas von Hahn
    Center for the Study of Hepatitis C, The Rockefeller University, New York, New York 10021, USA
    Gastroenterology 132:667-78. 2007
    ....
  18. pmc Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes
    Wayne D Crill
    Arbovirus Diseases Branch, Division of Vector Borne Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, U S Department of Health and Human Services, P O Box 2087, Fort Collins, CO 80522, USA
    J Virol 78:13975-86. 2004
    ..The third epitope consists of discontinuous residues that are structurally related to the strictly conserved tryptophan at dengue virus serotype 2 E-glycoprotein position 231...
  19. pmc Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity
    Claire M Midgley
    Department of Medicine, Hammersmith Hospital Campus, Imperial College London, London W12 0NN, United Kingdom
    J Immunol 188:4971-9. 2012
    ..Surprisingly, 2H12 facilitated little or no enhancement of infection. These data provide a structural basis for understanding Ab neutralization and enhancement of infection, which is crucial for the development of future dengue vaccines...
  20. pmc Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors
    Elin S Gray
    AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, Private Bag X4, Sandringham 2131, Johannesburg, South Africa
    J Virol 83:8925-37. 2009
    ....
  21. pmc An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys
    Minetaro Arita
    Department of Virology II, National Institute of Infectious Diseases, 4 7 1 Gakuen, Musashimurayama shi, Tokyo 208 0011, Japan
    J Virol 81:9386-95. 2007
    ..In the CNS, EV71(S1-3') was isolated only from the spinal cord. These results indicate that EV71(S1-3') acts as an effective antigen, although this attenuated strain was still neurotropic when inoculated via the intravenous route...
  22. pmc Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop
    Penny L Moore
    National Institute for Communicable Diseases of the NHLS, Private Bag X4, Sandringham 2131, Johannesburg, South Africa
    J Virol 85:3128-41. 2011
    ....
  23. pmc Heterologous immunity between viruses
    Raymond M Welsh
    Department of Pathology, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Immunol Rev 235:244-66. 2010
    ..We propose that heterologous immunity is an important factor in resistance to and variations of human viral infections and that issues of heterologous immunity should be considered in the design of vaccines...
  24. pmc Cross-reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses
    Stephanie Gras
    Protein Crystallography Unit, Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia
    Proc Natl Acad Sci U S A 107:12599-604. 2010
    ....
  25. pmc In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection
    Ruklanthi de Alwis
    Department of Microbiology and Immunology, and the Southeast Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research, University of North Carolina School of Medicine, Chapel Hill, NC, USA
    PLoS Negl Trop Dis 5:e1188. 2011
    ..Our MAbs results indicate that, in these two individuals exposed to primary DENV infections, a small fraction of the total antibody response was responsible for virus neutralization...
  26. ncbi Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression
    Zelda Euler
    Department of Experimental Immunology, Landsteiner Laboratory Sanquin Research, and Center for Infection and Immunity, Academic Medical Center at the University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
    J Infect Dis 201:1045-53. 2010
    ..Our findings underscore the importance of vaccine-elicited immunity in protecting from infection. The association between CD4(+) T cell counts and neutralizing humoral immunity may provide new clues as to how to achieve this goal...
  27. pmc Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection
    S Munir Alam
    Human Vaccine Institute, Box 3258, Duke University Medical Center, MSRBII Bldg, Room 4042, Durham, NC 27710, USA
    J Virol 82:115-25. 2008
    ....
  28. pmc Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity
    Zelda Euler
    Department of Experimental Immunology, Sanquin Research, Landsteiner Laboratory, Center for Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Virol 86:2045-55. 2012
    ..A better understanding of the underlying factors that determine the presence of CrNA or even an elite neutralizer phenotype may aid in the design of an HIV-1 vaccine...
  29. pmc Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120
    Anna Forsman
    MRC UCL Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, 46 Cleveland Street, London W1T 4JF, United Kingdom
    J Virol 82:12069-81. 2008
    ..Antienvelope VHH might also prove useful in defining neutralizing and nonneutralizing epitopes on HIV-1 envelope proteins, with implications for HIV-1 vaccine design...
  30. ncbi Inactivated trivalent seasonal influenza vaccine induces limited cross-reactive neutralizing antibody responses against 2009 pandemic and 1934 PR8 H1N1 strains
    Vernon J Lee
    Biodefence Center, Singapore Armed Forces, 701 Transit Road 04 01, Singapore 778910, Singapore
    Vaccine 28:6852-7. 2010
    ..In June 2009, we conducted a prospective study in Singapore on 51 individuals to determine their serologic responses before and following receipt of the 2009 Southern Hemisphere seasonal influenza vaccine...
  31. pmc An in-depth analysis of original antigenic sin in dengue virus infection
    Claire M Midgley
    Department of Medicine, Hammersmith Hospital Campus, Imperial College London, London, United Kingdom
    J Virol 85:410-21. 2011
    ..On the basis of these findings, we propose a simple in vitro enzyme-linked immunosorbent assay (ELISA) to diagnose the original dengue infection in secondary dengue cases...
  32. pmc Vaccine potential of the Neisseria meningitidis 2086 lipoprotein
    Leah D Fletcher
    Wyeth Vaccines Research, Pearl River, New York 10965, USA
    Infect Immun 72:2088-100. 2004
    ..The rLP2086 family of antigens are candidates worthy of further vaccine development...
  33. pmc Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines
    Balaji Manicassamy
    Department of Microbiology, Mount Sinai School of Medicine, New York, New York, United States of America
    PLoS Pathog 6:e1000745. 2010
    ..Our results also support the notion that pigs can act as an animal reservoir where influenza virus HAs become antigenically frozen for long periods of time, facilitating the generation of human pandemic viruses...
  34. ncbi Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
    Steven M Jones
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba R3E 3R2, Canada
    Nat Med 11:786-90. 2005
    ..No evidence of EBOV or MARV replication was detected in any of the protected animals after challenge. Our data suggest that these vaccine candidates are safe and highly efficacious in a relevant animal model...
  35. pmc Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4(+) T cells against the swine-origin H1N1 influenza virus
    Brian C Schanen
    Sanofi Pasteur, VaxDesign Campus, Orlando, FL 32826, USA
    Vaccine 29:3299-309. 2011
    ....
  36. pmc Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5
    Nobuko Ohshima
    Division of Antibody Project, Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Aichi 470 1192, Japan
    J Virol 85:11048-57. 2011
    ..The possible epitope recognized by these clones is discussed...
  37. pmc Preexisting antibody response against 2009 pandemic influenza H1N1 viruses in the Taiwanese population
    Chia Yu Chi
    Division of Infectious Diseases, National Health Research Institutes, Tainan, Taiwan
    Clin Vaccine Immunol 17:1958-62. 2010
    ..Our data also indicate that natural infection with the Taiwan 2006 and 2008 seasonal H1N1 viruses may induce a cross-reactive antibody response to the 2009 pH1N1 virus...
  38. pmc A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein
    Yong qiang Deng
    State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
    PLoS ONE 6:e16059. 2011
    ..These results define a novel broadly flavivirus cross-reactive mAb with highly neutralizing activity that can be further developed as a therapeutic agent against severe flavivirus infections in humans...
  39. ncbi The Guillain-Barré syndrome: a true case of molecular mimicry
    C Wim Ang
    Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Trends Immunol 25:61-6. 2004
    ..Based on recent evidence, we argue that GBS should be considered as an excellent paradigm and an attractive model for elucidation of both host and microbial aspects of molecular mimicry...
  40. pmc Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells
    Mark Throsby
    Crucell Holland BV, Leiden, The Netherlands
    PLoS ONE 3:e3942. 2008
    ..Furthermore, there are 16 different HA subtypes and no certainty the next pandemic will be caused by an H5 subtype, thus it is important to develop prophylactic and therapeutic interventions that provide heterosubtypic protection...
  41. pmc Var2CSA DBL6-epsilon domain expressed in HEK293 induces limited cross-reactive and blocking antibodies to CSA binding parasites
    Pablo Fernandez
    Institut Pasteur, Unité de Biologie des Interactions Hôte Parasite, CNRS URA2581, Batiment Nicolle, 25 rue du Docteur Roux, F 75724 Paris Cedex 15, France
    Malar J 7:170. 2008
    ..However, designing such a prophylactic vaccine has been hindered by the difficulty in identifying regions of var2CSA that could elicit broadly neutralizing and adhesion-blocking antibodies...
  42. pmc Evaluation of the antigenic diversity of placenta-binding Plasmodium falciparum variants and the antibody repertoire among pregnant women
    Mirja Hommel
    The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3050, Australia
    Infect Immun 78:1963-78. 2010
    ..Inclusion of a limited number of variants in a candidate vaccine may be sufficient for broad population coverage, but geographic considerations may also have to be included in vaccine design...
  43. pmc Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites
    Karin Stiasny
    Institute of Virology, Medical University of Vienna, Kinderspitalgasse 15, A 1095 Vienna, Austria
    J Virol 80:9557-68. 2006
    ....
  44. pmc Toward a broadly protective influenza vaccine
    Peter C Doherty
    Department of Microbiology and Immunology, University of Melbourne, Melbourne, Victoria, Australia
    J Clin Invest 118:3273-5. 2008
    ..These peptides could be used to add a CD8+ T cell component to current antibody-focused vaccine strategies with a view to reducing the impact of infection with novel influenza A viruses...
  45. ncbi The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice
    R M Martin
    The Walter and Eliza Hall Institute of Medical Research, P O Royal Melbourne Hospital, Parkville, Victoria, Australia
    J Immunol Methods 212:187-92. 1998
    ..We have used DNA immunization to generate polyclonal anti-IgG2c serum and demonstrated that it is essential to use IgG2c-specific antiserum to quantify accurately isotypic responses in mouse strains with the Igh1-b allele...
  46. pmc Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II
    Chih Yun Lai
    Institute of Microbiology, College of Medicine, National Taiwan University, Taipei, Taiwan
    J Virol 82:6631-43. 2008
    ..These findings have implications for our understanding of the pathogenesis of dengue and for the future design of subunit vaccine against DENV as well...
  47. pmc Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses
    Andres G Grandea
    Theraclone Sciences, Seattle, WA 98104, USA
    Proc Natl Acad Sci U S A 107:12658-63. 2010
    ..Accordingly, recombinant forms of these human antibodies may provide useful therapeutic agents to protect against infection from a broad spectrum of influenza A strains...
  48. pmc Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes
    Catarina E Hioe
    Department of Pathology, New York University Langone School of Medicine, New York, New York, United States of America
    PLoS ONE 5:e10254. 2010
    ..Despite this evidence of V3 conservation, the ability of anti-V3 Abs to neutralize a significant proportion of HIV-1 isolates from different subtypes (clades) has remained controversial...
  49. ncbi IgE cross-reactivity between Ascaris lumbricoides and mite allergens: possible influences on allergic sensitization and asthma
    N Acevedo
    Institute for Immunological Research, University of Cartagena, Cartagena, Colombia
    Parasite Immunol 33:309-21. 2011
    ..In this review, we discuss the potential role of this cross-reactivity on several aspects of allergy in the tropics that have been a focus of a number of investigations, some of them with controversial results...
  50. ncbi Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression
    Marit J van Gils
    Department of Experimental Immunology, Landsteiner Laboratory Sanquin Research, and Center for Infection and Immunity CINIMA, Academic Medical Center at the University of Amsterdam, Amsterdam, The Netherlands
    AIDS 23:2405-14. 2009
    ..However, little is known about the prevalence of naturally occurring broadly neutralizing activity in serum of HIV-1-infected individuals...
  51. pmc Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus
    Jonathan A McCullers
    Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Clin Infect Dis 50:1487-92. 2010
    ..Receipt of a vaccine to a related virus significantly enhanced the neutralization capacity of these responses, suggesting homologous vaccination against the 2009 pandemic H1N1 influenza virus would have a similar effect...
  52. ncbi Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region
    Kazunari Kondo
    Center for Pathogen Genomics, National Institute of Infectious Diseases, 1 23 1 Toyama, Shinjuku ku, Tokyo 162 8640, Japan
    Virology 358:266-72. 2007
    ..The cross-neutralization appears to be correlated with conserved aa sequences among HPV types. The data in this study provide a basis for designing vaccine antigens effective against a broader spectrum of the high-risk HPVs...
  53. ncbi Ara h 8, a Bet v 1-homologous allergen from peanut, is a major allergen in patients with combined birch pollen and peanut allergy
    Diana Mittag
    Department of Dermatology, University Hospital, Zurich
    J Allergy Clin Immunol 114:1410-7. 2004
    ..We recently described patients with soybean allergy mainly mediated by cross-reactivity to birch pollen allergens. A majority of those patients were reported to have peanut allergy...
  54. pmc Seroconversion to pandemic (H1N1) 2009 virus and cross-reactive immunity to other swine influenza viruses
    Ranawaka A P M Perera
    The University of Hong Kong, Hong Kong Special Administrative Region, People s Republic of China
    Emerg Infect Dis 17:1897-9. 2011
    ..Results indicated that infection with pandemic (H1N1) 2009 broadens cross-reactive immunity to other recent subtype H1 swine viruses...
  55. ncbi Birch pollen-related food allergy to legumes: identification and characterization of the Bet v 1 homologue in mungbean (Vigna radiata), Vig r 1
    D Mittag
    Allergy Unit, Department of Dermatology, University Hospital, Zurich, Switzerland
    Clin Exp Allergy 35:1049-55. 2005
    ..In this study we assessed allergic reactions to another legume, to mungbean seedlings, and identified its Bet v 1-homologous allergen Vig r 1...
  56. pmc Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection
    Scott A Smith
    Department of Medicine, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, USA
    J Virol 86:2665-75. 2012
    ..Such principles could be used in the rational design of vaccines that enhance the induction of neutralizing antibodies, while lowering the risk of dengue shock syndrome...
  57. ncbi IgE cross-reactivity between the major peanut allergen Ara h 2 and the nonhomologous allergens Ara h 1 and Ara h 3
    Merima Bublin
    Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria
    J Allergy Clin Immunol 132:118-24. 2013
    ..Ara h 2 is an important predictor of clinical reactivity to peanut, but cosensitization to all 3 allergens is correlated with the severity of patients' symptoms...
  58. pmc Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein
    Mario Perotti
    Laboratorio di Microbiologia e Virologia, Universita Vita Salute San Raffaele, DIBIT2, Via Olgettina 60, 20132 Milano, Italia
    J Virol 82:1047-52. 2008
    ..Fab e137 was also able to inhibit cell culture-grown HCV (genotype 2a). These data indicate that broadly cross-reacting and cross-neutralizing antibodies are generated during HCV infection...
  59. ncbi A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans
    Klaus K Orlinger
    Global Research and Development, Baxter BioScience, Vienna, Austria
    J Infect Dis 203:1556-64. 2011
    ....
  60. ncbi Cross-immunity experiments between different species or strains of Leishmania in rhesus macaques (Macaca mulatta)
    Renato Porrozzi
    Departments of Immunology and Ultrastructural and Cell Biology, Instituto Oswaldo Cruz FIOCRUZ, Rio de Janeiro, Brazil
    Am J Trop Med Hyg 71:297-305. 2004
    ..Further studying the immune response may provide information regarding relevant factors influencing cross-protective immunity...
  61. pmc Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection
    Soila Sukupolvi-Petty
    Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    J Virol 87:8826-42. 2013
    ..Our studies establish the complexity of MAb recognition against DENV-4 and suggest that differences in epitope exposure relative to other DENV serotypes affect antibody neutralization and protective activity. ..
  62. ncbi Development of an IgM-capture ELISA for Coxsackievirus A16 infection
    Feihai Xu
    National Institute of Diagnostics and Vaccine Development in Infectious Disease, Xiamen University, Xiamen, China
    J Virol Methods 171:107-10. 2011
    ..The cross-reaction rate in patients infected with other non-CA16 enteroviruses was 9.7% (14/144). These results suggest that the IgM anti-CA16 assay offers a rapid, convenient, and reliable method to detect acute CA16 infections...
  63. pmc T cell-mediated protection against lethal 2009 pandemic H1N1 influenza virus infection in a mouse model
    Hailong Guo
    David H Smith Center for Vaccine Biology and Immunology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 609, Rochester, NY 14642, USA
    J Virol 85:448-55. 2011
    ..Our results highlight the importance of establishing cross-reactive T-cell responses for protecting against existing or newly emerging pandemic influenza viruses...
  64. ncbi Ancestral and consensus envelope immunogens for HIV-1 subtype C
    Denise L Kothe
    Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Virology 352:438-49. 2006
    ..These results establish the utility of centralized HIV-1 subtype C Env immunogens and warrant their continued evaluation as potential components of future AIDS vaccines...
  65. ncbi Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1
    Gary R McLean
    Department of Respiratory Medicine, National Heart and Lung Institute, Imperial College London, London, UK
    Antiviral Res 95:193-201. 2012
    ..Immunisation strategies boosted homotypic as well as inducing cross-serotype neutralising IgG responses. We conclude that VP1 based antigens combined with adjuvants may permit successful antibody-mediated vaccine design and development...
  66. pmc A triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza H5N1 viruses
    Fan Zhou
    Unit of Anti Viral Immunity and Genetic Therapy, Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China
    J Virol 86:6970-8. 2012
    ..Further evaluation and optimization of such an approach in ferrets and in humans is warranted...
  67. pmc A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection
    Saori Sakabe
    Institute of Medical Science, University of Tokyo, Minato ku, Japan
    Antiviral Res 88:249-55. 2010
    ..Our results suggest that direct administration of this anti-influenza antibody to viral replication sites is an effective strategy for prophylaxis and therapy...
  68. ncbi IgE to peanut allergen components: relation to peanut symptoms and pollen sensitization in 8-year-olds
    A Asarnoj
    National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Allergy 65:1189-95. 2010
    ..The aim was to investigate IgE reactivity to peanut allergen components in children from a birch-rich region in relation to pollen sensitization and peanut symptoms...
  69. pmc Novel vaccines against influenza viruses
    S M Kang
    Center for Inflammation, Immunity and Infection, Department of Biology, Georgia State University, 100 Piedmont Avenue, 7th Floor 718, Atlanta, GA 30303, United States
    Virus Res 162:31-8. 2011
    ..In addition, recent studies provide evidence that vaccine supplements can provide avenues to further improve current vaccies...
  70. ncbi Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis
    Vesna Blazevic
    Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
    Vaccine 29:8126-33. 2011
    ..Rather, we observed an adjuvant effect of rVP6 on the NoV-specific homologous and heterologous immune responses to genotypes not included in a vaccine formulation...
  71. pmc A conserved multi-gene family induces cross-reactive antibodies effective in defense against Plasmodium falciparum
    Subhash Singh
    Bio medical Parasitology Unit, Institut Pasteur, Paris, France
    PLoS ONE 4:e5410. 2009
    ..Both MSP3 and MSP6 share a common characteristic small N-terminal signature amino-acid stretch (NLRNA/G), a feature similar to MSP3-like orthologs identified in other human and primate malaria parasites...
  72. pmc Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development
    Mariette F Ducatez
    Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN 38105 3678, USA
    Proc Natl Acad Sci U S A 108:349-54. 2011
    ..Such technologies should be explored to enhance the cross reactivity and availability of H5N1 influenza vaccines...
  73. ncbi Comparisons of the genetic and neutralization properties of HIV-1 subtype C and CRF07/08_BC env molecular clones isolated from infections in China
    Suting Wang
    Department of Cellular Biology, National Institute for the Control of Pharmaceutical and Biological Products, No 2 Tiantanxili, Beijing 100050, China
    Virus Res 155:137-46. 2011
    ..These findings are likely to provide useful information for the design and evaluation of HIV-1 neutralizing antibody-based vaccine development in China...
  74. pmc Specific serodiagnosis of canine visceral leishmaniasis using Leishmania species ribosomal protein extracts
    Eduardo A F Coelho
    Departamento de Bioquimica e Imunologia, ICB, Universidade Federal de Minas Gerais, 31 270 901, Belo Horizonte, Minas Gerais, Brazil
    Clin Vaccine Immunol 16:1774-80. 2009
    ..Our findings suggest that LRPs are a potential tool for the diagnosis of CVL and will be particularly useful for the diagnosis of asymptomatic CVL...
  75. ncbi New tools to monitor the impact of viral infection on the alloreactive T-cell repertoire
    L J D'Orsogna
    Department of Immunohematology and Blood Transfusion, Leiden University Medical Centre, Leiden, The Netherlands
    Tissue Antigens 74:290-7. 2009
    ..This technique may have important implications for donor selection and monitoring of transplant recipients...
  76. pmc The NS1 glycoprotein can generate dramatic antibody-enhanced dengue viral replication in normal out-bred mice resulting in lethal multi-organ disease
    Andrew K I Falconar
    Grupo de Investigaciones en Enfermedades Tropicales, Departmento de Ciéncias Básicas Medicas, Universidad del Norte, Barranquilla, Colombia
    PLoS ONE 6:e21024. 2011
    ..The model provides potential for assessing DENV strain pathogenicity and anti-DENV therapies in normal mice...
  77. ncbi Quantitative and functional diversity of cross-reactive EBV-specific CD8+ T cells in a longitudinal study cohort of lung transplant recipients
    Nicole A Mifsud
    Department of Medicine, Monash University, Central Clinical School, The Alfred Hospital, Melbourne, Victoria, Australia
    Transplantation 90:1439-49. 2010
    ....
  78. ncbi Microarray of allergenic component-based diagnosis in food allergy
    Maria L Sanz
    Departamento de Alergología e Inmunología Clínica, Clinica Universidad de Navarra, Pamplona, Spain
    Curr Opin Allergy Clin Immunol 11:204-9. 2011
    ..In this review, we will analyze the results obtained to date with this technology applied to the component-based diagnosis of food allergy...
  79. pmc Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics
    Josh D Nelson
    Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Virology 377:170-83. 2008
    ..Nevertheless, the mAb panel may be useful as tools for elucidating access restrictions to the NHR of gp41 and in designing potential improvements to mimetics of receptor-activated Env...
  80. ncbi Component-resolved diagnosis of house-dust mite allergy with purified natural and recombinant mite allergens
    G Pittner
    Division of Immunopathology, Department of Pathophysiology, Vienna General Hospital, Medical University of Vienna, Austria
    Clin Exp Allergy 34:597-603. 2004
    ..Immunotherapy with mite allergen extracts is frequently performed if allergen avoidance is not possible or successful. However, highly controversial results have been reported for mite-specific immunotherapy...
  81. pmc Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation
    Hugo Mouquet
    Laboratory of Molecular Immunology, The Rockefeller University, New York, New York 10065, USA
    Nature 467:591-5. 2010
    ..Despite the low affinity of the polyreactive combining site, heteroligation demonstrably increases the apparent affinity of polyreactive antibodies to HIV...
  82. ncbi Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins
    A K Falconar
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, U K
    Arch Virol 144:2313-30. 1999
    ..These peptide sequence will now be tested for their ability to generate cross-protective antibodies against each dengue virus serotype when delivered with appropriate T-helper epitopes...
  83. ncbi Adenovirus-based vaccines generate cytotoxic T lymphocytes to epitopes of NS1 from dengue virus that are present in all major serotypes
    Guangping Gao
    Vaccine Research Institute, Sun Yat Sen University, Guangzhou, 510630, China
    Hum Gene Ther 19:927-36. 2008
    ....
  84. ncbi Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine
    Paul A Tambyah
    National University Hospital, 5 Lower Kent Ridge Road, Singapore
    Vaccine 30:329-35. 2012
    ..The H5N1 influenza vaccine against clade 2.1 strain A/Indonesia/05/2005 was well tolerated and immunogenic after two vaccinations, and induced a cross-neutralizing antibody response, with no dose effect...
  85. ncbi nsLTP and profilin are allergens in mustard seeds: cloning, sequencing and recombinant production of Sin a 3 and Sin a 4
    S Sirvent
    Departament of Biochemistry and Molecular Biology, Complutense University of Madrid, Madrid, Spain
    Clin Exp Allergy 39:1929-36. 2009
    ..Patients allergic to mustard are frequently sensitized to peach...
  86. ncbi Biochemical, immunological and clinical characterization of a cross-reactive nonspecific lipid transfer protein 1 from mulberry
    M A Ciardiello
    Institute of Protein Biochemistry, Consiglio Nazionale delle Ricerche, Napoli, Italy
    Allergy 65:597-605. 2010
    ..is a genus comprising several species of deciduous trees whose fruits are commonly eaten in southern Europe. Subjects with severe systemic reaction have been described. The aim of this study was to isolate the allergens of this species...
  87. pmc Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries
    Arun K Kashyap
    Sea Lane Biotechnologies, Menlo Park, California, United States of America
    PLoS Pathog 6:e1000990. 2010
    ..These results demonstrate broad activity of the A06 antibody and its utility as an anti-influenza treatment option, even against newly evolved influenza strains to which there is limited immunity in the general population...
  88. ncbi Prevalence of sensitization to Artemisia allergens Art v 1, Art v 3 and Art v 60 kDa. Cross-reactivity among Art v 3 and other relevant lipid-transfer protein allergens
    M Lombardero
    Dept I D, ALK Abelló SA, Madrid, Spain
    Clin Exp Allergy 34:1415-21. 2004
    ..One of them, Art v 3, belongs to the lipid-transfer protein (LTP) family and its prevalence in Artemisia-sensitized patients or its relationship with other LTP allergens is not clear...
  89. pmc Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species
    Lisa E Hensley
    Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA
    PLoS Pathog 6:e1000904. 2010
    ....
  90. pmc Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects
    D Noah Sather
    Seattle Biomedical Research Institute, Seattle, WA 98109, United States
    Vaccine 28:B8-12. 2010
    ..Overall, our study indicates that more than one pathway leads to the development of broad cross-reactive NAbs during HIV-infection...
  91. pmc Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals
    Laurel Yong Hwa Lee
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    J Clin Invest 118:3478-90. 2008
    ..Thus, vaccine formulas inducing heterosubtypic T cell-mediated immunity may confer broad protection against avian and human influenza A viruses...
  92. pmc Assessment of seasonal influenza A virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swine-origin influenza A virus
    Xinhui Ge
    Benaroya Research Institute at Virginia Mason, Seattle, WA 98101, USA
    J Virol 84:3312-9. 2010
    ..These findings suggest that without protective antibody responses, individuals vaccinated against seasonal influenza A may still benefit from preexisting cross-reactive memory CD4 T cells reducing their susceptibility to S-OIV infection...
  93. pmc Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia
    M Medina-Ramírez
    Retrovirology and Viral Immunopathology Laboratory, IDIBAPS, Hospital Clinic, University of Barcelona, Villarroel 170, Barcelona, Spain
    J Virol 85:5804-13. 2011
    ..This observation is in stark contrast to the data obtained from long-term nonprogressors, whose little neutralizing activity has been attributed to the low levels of viral replication...
  94. pmc A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11
    Katharina Slupetzky
    Laboratory of Viral Oncology, Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Vaccine 25:2001-10. 2007
    ..Induction of cross-neutralization Ab by L2 epitopes displayed on chimeric VLP represents a possible strategy for the generation of broad-spectrum vaccines to protect against relevant mucosal HPV and associated neoplasia...
  95. pmc Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines
    John Donnelly
    Novartis Vaccines and Diagnostics, 53100 Siena, Italy
    Proc Natl Acad Sci U S A 107:19490-5. 2010
    ..This assay allows typing of large panels of strains and prediction of coverage of protein-based meningococcal vaccines. Similar assays may be used for protein-based vaccines against other bacteria...
  96. ncbi Cross-reactivity studies of an anti-Plasmodium vivax apical membrane antigen 1 monoclonal antibody: binding and structural characterisation
    Sebastien Igonet
    Unité d Immunologie Structurale, CNRS URA 2185, Departement de Biologie Structurale et Chimie, Institut Pasteur, 25 rue du Dr Roux, 75724 Paris Cedex 15, France
    J Mol Biol 366:1523-37. 2007
    ..The implications for AMA1 vaccine development are discussed...
  97. pmc High pro-inflammatory cytokine secretion and loss of high avidity cross-reactive cytotoxic T-cells during the course of secondary dengue virus infection
    Tao Dong
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    PLoS ONE 2:e1192. 2007
    ..Generally attributed to the phenomenon of antibody-dependent enhancement, recent observations indicate that T-cells may also influence disease phenotype...
  98. ncbi IgE cross-reactivity between Ascaris and domestic mite allergens: the role of tropomyosin and the nematode polyprotein ABA-1
    N Acevedo
    Institute for Immunological Research, University of Cartagena, Cartagena, Colombia
    Allergy 64:1635-43. 2009
    ..The objective of this study was to investigate immunoglobulin E (IgE) cross-reactivity between Ascaris and two domestic mites in the tropics...
  99. pmc T cell cross-reactivity and conformational changes during TCR engagement
    Jean K Lee
    Human Immunology Unit, Medical Research Council, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, England, UK
    J Exp Med 200:1455-66. 2004
    ..These findings have implications for the rational design of vaccines targeting viruses with unstable genomes...
  100. ncbi Evaluation of hemagglutinin subtype 1 swine influenza viruses from the United States
    Amy L Vincent
    Virus and Prion Diseases of Livestock Research Unit, National Animal Disease Center, USDA, ARS, Ames, IA 50010, USA
    Vet Microbiol 118:212-22. 2006
    ..S. pig population exhibit considerable variability in pathogenicity. There appears to be an increase in genetic and antigenic diversity coincident with the emergence of the swine triple reassortant H3N2 in 1998...
  101. pmc Evidence for globally shared, cross-reacting polymorphic epitopes in the pregnancy-associated malaria vaccine candidate VAR2CSA
    Marion Avril
    Seattle Biomedical Research Institute, 307 Westlake Ave N, Suite 500, Seattle, WA 98109 5219, USA
    Infect Immun 76:1791-800. 2008
    ..This study demonstrates that VAR2CSA contains common polymorphic epitopes that are shared between geographically diverse CSA-binding lines...

Research Grants65

  1. Prediction of influenza antigenic variants using a novel sparse multitask learnin
    Xiu Feng Wan; Fiscal Year: 2010
    ..This method will also be applied in studying antigenic drift patterns leading to influenza outbreak and epidemics. ..
  2. HUMAN HYBRIDOMAS IN THE ANALYSIS OF AUTOIMMUNE DISEASE
    BERNARD STOLLAR; Fiscal Year: 1990
    ..His laboratory will also test for auto-anti-idiotype antibodies in both hybridoma cultures and in sera, and determine whether their concentrations fluctuate in relation to disease activity...
  3. MOLECULAR STRUCTURE OF STEROIDS
    William Duax; Fiscal Year: 2006
    ..members of each STOR subfamily, information will be obtained regarding their binding affinities and cross reactions that will be useful for the design of selective inhibitors...
  4. STRUCTURE AND BIOSYNTHESIS OF ANTIBODIES
    Alfred Nisonoff; Fiscal Year: 1980
    ..We will also determine whether this factor preferentially induces the proliferation of antiidiotypic suppressor T-cells and whether the antiidiotypic T-cells can induce idiotype-positive suppressors. ..
  5. EPITOPE DISCOVERY--NEW ROUTE TO VACCINES
    George Smith; Fiscal Year: 2002
    ..abstract_text> ..
  6. Molecular Epidemiology, Virulence, and Genomic Characterization of Ureaplasmas
    Ken B Waites; Fiscal Year: 2010
    ....
  7. IMMUNE RESPONSES TO YERSINIA IN THYROID DISEASE
    Louis Shenkman; Fiscal Year: 1980
    ....
  8. HUMAN GR A CHO ANTIBODIES & THEIR PHAGOCYTIC PROPERTIES
    JOHN ZABRISKIE; Fiscal Year: 1999
    ..5. The anti-A CHO antibodies from rabbits, mice, and humans will then be examined for cross reactions with mammalian antigens or cytoskeletal proteins by immunofluorescence and ELISA.
  9. CROSS-REACTIONS BETWEEN FETAL, SPERM AND TUMOR CELLS
    SEI TOKUDA; Fiscal Year: 1980
    ..These studies should enable a more comprehensive understanding of the immunochemical nature of tumor-associated antigens and of the consequences of immune reactions against these antigens. ..
  10. REGULATION OF NATURAL KILLER CELLS
    Raymond Welsh; Fiscal Year: 2005
    ..This work should clarify how these effector systems act and interact to rid the host of infectious agents and tumors. ..
  11. IMMUNITY AND VIRUS DISEASE
    Raymond Welsh; Fiscal Year: 2003
    ..By manipulating this highly defined LCMV model in vivo, fundamental concepts concerning immunoregulation and immune deficiencies applicable to human viral infections should be obtained. ..
  12. VIRUS INDUCED IMMUNOPATHOLOGY
    Raymond Welsh; Fiscal Year: 2008
    ..SPECIFIC AIM #4. To determine the basis for the deficiency of virus-specific T cells in the homeostatic reconstitution of lymphopenic environments. ..
  13. IMMUNITY IN SYSTEMIC AND MUCOSAL VIRUS INFECTIONS
    LIISA SELIN; Fiscal Year: 2009
    ..Examine the mechanisms involved in augmented viral replication and immunopathology during LCMV or MCMV infection of influenza-immune mice. Specific Aim #4. Define the role of cytokines in mediating heterologous immunity. ..
  14. Ab Alphavirus Replicon Vaccine against Cytomegalovirus
    Robert Esch; Fiscal Year: 2005
    ..PROPOSED COMMERCIAL APPLICATIONS: An effective CMV vaccine will prevent mental retardation and hearing loss associated with congenital CMV disease, thereby addressing an important unmet public health problem. ..
  15. Genetics of Autontibody Diversification
    Umesh Deshmukh; Fiscal Year: 2008
    ..The proposal addresses a significant issue in autoimmunity and will serve well as a training vehicle to obtain the stated goals by the PI. ..
  16. Immune reactivity to synapsin in the neuropathy and ataxia of celiac disease
    Armin Alaedini; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  17. EVOLUTIONARY MODELS OF THE IMMUNE SYSTEM
    Melvin Cohn; Fiscal Year: 2010
    ..The influx of mathematicians and computer modelers is clearly changing the way we analyze immune behavior. ..
  18. OspA and autoimmunity in chronic Lyme disease
    Armin Alaedini; Fiscal Year: 2007
    ..Identification of specific immune reactivity to an autoantigen might also be useful as a diagnostic marker and for monitoring of disease activity in affected patients. [unreadable] [unreadable] [unreadable]..
  19. Nuclease-Resistant Aptamers to Botox and Anthrax Toxins
    John Bruno; Fiscal Year: 2004
    ..Such reagents could also be used in environmental biosensors or diagnostic test kits for detection of BOTOX and anthrax toxins in body fluids or environmental samples. ..
  20. Nuclease-Resistant Aptamers for Anthrax Opsonization
    John Bruno; Fiscal Year: 2004
    ..Such shielded aptamers could even be used in inhalers to enhance alveolar macrophage phagocytosis. ..
  21. Scanning B. pseudomallei proteome for vaccine antigens
    Philip Felgner; Fiscal Year: 2008
    ..pseudomallei in humans and experimental animals and will identify the most effective candidate antigens for development of a DNA or subunit vaccine against human melioidosis and glanders. ..
  22. Aging and Immunity Workshop
    Laura Haynes; Fiscal Year: 2004
    ..In this proposal, we are specifically requesting funds to cover the basic costs to allow five junior investigators to attend the workshop, with the goal of fostering the next generation of immunologists in this field. ..
  23. THE MECHANISMS OF AUTOIMMUNE RESPONSE INITIATION IN MULTIPLE SCLEROSIS
    Silva Markovic Plese; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  24. Lyophilization of Plasmodium falciparum sporozoite vaccine
    Stephen Hoffman; Fiscal Year: 2007
    ..Additionally, a dried vaccine may accelerate a concerted world-wide effort to eradicate this devastating disease. [unreadable] [unreadable] [unreadable]..
  25. MYOSIN--A LINK BETWEEN STREPTOCOCCI AND HEART
    Madeleine Cunningham; Fiscal Year: 2008
    ..r37 ..
  26. Individualized Interventions to Improve Asthma Adherence
    Andrea Apter; Fiscal Year: 2009
    ..We will estimate the incremental cost-effectiveness of PS. ..
  27. Development of De-immunized Botulinum Neurotoxin Type A for Dystonia
    Anne De Groot; Fiscal Year: 2008
    ..Public Health Relatedness: Knowledge of the elements of botulinum neurotoxin type A that give rise to its immunogenicity will contribute to the development of improved dystonia therapy. [unreadable] [unreadable] [unreadable]..
  28. HIV Vaccines that Elicit Immune Responses to Virus Env
    Catarina E Hioe; Fiscal Year: 2010
    ..These studies will provide information about how to design more immunogenic forms of gp120, how to better stimulate gp120-specific CD4 T cell responses, and how to use the mutated gp120 constructs as HIV vaccines. ..
  29. Molecular Basis of Gamma Delta TCR Ligand Recognition
    KENAN GARCIA; Fiscal Year: 2009
    ..Finally, we will begin to investigate whether the structural basis of gammadelta TCR recognition of non-MHC protein antigens is fundamentally different from 78 TCR recognition of MHC-like antigens. ..
  30. THE ROLE OF CHEMOKINES IN AUTOIMMUNE ENCEPHALOMYELITIS
    William Karpus; Fiscal Year: 2009
    ..These studies will help to understand the immunopathogenesis of MS and provide a basis for the development of novel chemokine and chemokine receptor therapies for treatment of ongoing disease. ..
  31. Disruption of Innate Immune Function by P.Gingivalis Phosphotidylethanolamine Lip
    Toshihisa Kawai; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  32. Mucosal Protection Against HIV Transmission by Combinations of Anti-HIV Antibodie
    Lisa Cavacini; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  33. Genetically Attenuated Malaria Sporozote Vaccine
    Stephen Hoffman; Fiscal Year: 2008
    ..Success in this project has the potential to lead to development of a safe, effective, attenuated malaria vaccine. [unreadable] [unreadable] [unreadable]..
  34. Clinical Suspicion of TB: A Technology Assessment Tool
    Antonino Catanzaro; Fiscal Year: 2007
    ..It will help define the role of serologic testing in the diagnosis of PTB. ..
  35. Adrenergic Antagonism During Murine Candidiasis
    Brad Spellberg; Fiscal Year: 2008
    ..For these reasons, the potential for adrenergic antagonism to act as an effective immunotherapy is highly meritorious of investigation in this training application. ..
  36. Am Soc of Tropical Medicine and Hygiene Annual Meeting
    George Hillyer; Fiscal Year: 2008
    ..A critical need is to obtain financial support for graduate and postdoctoral students, our future specialists in the different areas of tropical medicine, to attend and be part of the annual meeting of this Society. ..
  37. Quantification of Host Markers in GCF Using CBIB
    Ricardo Teles; Fiscal Year: 2007
    ..Moreover, this methodology is at the forefront of new approaches in proteomics, and carries enormous promise for translational applications in the near future. [unreadable] [unreadable]..
  38. Polypeptide Hormone Receptor Recognition and Activation
    KENAN GARCIA; Fiscal Year: 2007
    ..abstract_text> ..
  39. The Role of Babesia bovis MSA-1 in Erythrocyte Invasion
    Tanya LeRoith; Fiscal Year: 2004
    ..The results of this project, as well as the transfection techniques that will be developed, will allow us to begin targeting regions of functional significance in these proteins for further study...
  40. Sex differences in Coxsackievirus-induced myocarditis
    Noel Rose; Fiscal Year: 2004
    ..The findings generated by these studies will aid in understanding the sex- based differences in severity in this model of infection-induced autoimmune disease. ..
  41. NCRR FACSAria Cell Sorter
    Barton Haynes; Fiscal Year: 2004
    ..Advisory committees, institutional support, financial support for continued maintenance, and management plans are in place to insure that the instrument will be fully and appropriately utilized. ..
  42. 2nd Orthomyxoviruses Research Conference
    Jonathan McCullers; Fiscal Year: 2003
    ..The purpose of this proposal is to provide funds that will allow promising young investigators to interact with their peers and develop a commitment to this area of research. ..
  43. EXPERIMENTAL PATHOLOGY SHARED RESOURCE LABORATORY
    Laura Lamps; Fiscal Year: 2003
    ..abstract_text> ..
  44. CONTROL OF PERIODONTAL INFECTIONS
    Sigmund Socransky; Fiscal Year: 2003
    ..Project D will examine the ecological relationships of oral species and their habitat. ..
  45. Intracellular Peptide Delivery Reagent
    Philip Felgner; Fiscal Year: 2002
    ..The understanding gained from this analysis will be applied to the design of peptides and reagent compositions to demonstrate functional intracellular peptide delivery. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE ..
  46. Intra-Oral Biofilm Formation
    Sigmund Socransky; Fiscal Year: 2004
    ..abstract_text> ..
  47. INSULIN RESISTANCE IN PCOS--SEQUELAE AND TREATMENT
    RICHARD LEGRO; Fiscal Year: 2005
    ..Improving insulin action through diet and exercise, with and without weight loss, will result in lowered circulating insulin levels, lowered androgens and increased ovulatory frequency rate in PCOS women. ..
  48. Mining slime mold for susceptibility genes to fungi
    Arturo Casadevall; Fiscal Year: 2005
    ..discoideum system will lead to the identification of genetic pathways that are not immediately obvious from standard fungal-macrophage experiments. ..
  49. Role of innate immunity in autoimmune myocarditis
    Noel Rose; Fiscal Year: 2005
    ..The findings generated by these studies will aid in understanding the development of autoimmune disease initiated by infection. ..
  50. Human monoclonal panel mimicking anthrax immune globulin
    Donald Reason; Fiscal Year: 2005
    ..The PA-specific panel we construct will be molecularly defined and characterized, incorporate the advantages of toxin-specific, polyclonal human sera, and lack the inherent risk associated with blood derived products. ..
  51. 3rd Orthomyxoviruses Research Conference
    Jonathan McCullers; Fiscal Year: 2005
    ..The purpose of this proposal is to provide funds that will allow promising young investigators to interact with their peers and develop a commitment to this area of research. ..
  52. MOLECULAR CHARACTERIZATION OF C NEOFORMANS ANTIBODIES
    Arturo Casadevall; Fiscal Year: 2006
    ..These studies are expected to yield new insights on fundamental aspects of antibody function as well as practical information for the development of second generation antibody reagents for human therapy. ..
  53. Role of Virus Recombination in Multiple Drug Resisitance
    Feng Gao; Fiscal Year: 2007
    ..Knowledge obtained from this study can be broadly applied toward understanding mechanisms of viral escape from immune surveillance and other selective forces. ..
  54. Lethal synergism between influenza and pneumococcus
    Jonathan McCullers; Fiscal Year: 2003
    ....
  55. Gamma Delta T cell and keratinocyte cross-talk in diabetic wounds
    Julie Jameson; Fiscal Year: 2006
    ..Results from this proposal may lead to new directions aimed at targeting DETC for future therapies and studying intra-epithelial gamma-delta T cells in other tissues affected by diabetes such as the gut. ..
  56. Immunogenicity of an HIV virus-like particle vaccine
    Feng Gao; Fiscal Year: 2004
    ..abstract_text> ..
  57. NOVEL EFFECTORS OF GRB2 IN HUMAN GLIAL TUMORS
    Albert Wong; Fiscal Year: 2009
    ..abstract_text> ..
  58. SARS Reverse Genetics
    Ralph Baric; Fiscal Year: 2008
    ..The goal of this application is to establish genetic control over the SARS genome and provide uniform reagents that will be used by other groups throughout the country. ..
  59. NEONATAL FC RECEPTOR/IGG INTERACTION
    PAMELA BJORKMAN; Fiscal Year: 2001
    ..5 to address the possibility of pH-dependent conformational changes. To answer the third question, mutants of FcRn with an open, MHC-like peptide-binding groove will be constructed and characterized. ..
  60. Novel Smallpox Vaccine Derived from VV/VAR Immunome
    Anne De Groot; Fiscal Year: 2006
    ..unreadable] [unreadable]..